AMERI Holdings (AMRH) Stock Runs On IRB Approval

AMERI Holdings AMRH Stock News

AMERI Holdings Inc (NASDAQ: AMRH) is rocketing in the market this morning, trading on gains that are better stated in multiples than percentages. the gains come after the company announced that its partner has received approval from the IRB to test a CBD-based drug as a potential treatment for brain cancer. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

AMRH Stock Rockets On Phase I/II Brain Cancer Trial

In the press release, AMERI Holdings said that its partner, Jay Pharma, has received IRB approval in Israel to start a Phase I/II clinical trial. During the trial, Jay Pharma’s proprietary cannabidiol formulation will be tested for the treatment of glioblastoma multiforme.

The trial will be an open-label, two-arm, randomized, perspective study. While the IRB has approved the study, it will not begin until approval is received by the Israel Ministry of Health. It is expected that the approval from regulatory authorities will take place this summer.

AMRH said that in the study, 40 patients with recurrent or progressive GBM tumors who are currently undergoing chemotherapy treatments will be enrolled. Half of the patients enrolled will be treated with the company’s synthetic CBD derived from citrus, and half will be treated with CBD in combination with clomiphene, an estrogen binding site inhibitor.

In a statement, Dr. Zvi Vogel, Professor of Neurobiology at the Weizmann Institute of Science had the following to offer:

Our initial work with CBD in combination with clomiphene has shown promise and look forward to working with Jay Pharma on combination therapy studies, with the ultimate goal of delivering FDA-approved combination therapies to cancer patients.

The above statement was followed up by Dave Johnson, CEO and Chairman-elect of the AMRH partner, Jay Pharma. Here’s what he had to say:

We believe that this clinical trial will further advance our understanding into how CBD affects this aggressive, rare and deadly cancer. Our focus on cannabinoid medicine is driven by our belief in its potential efficacy in palliative cancer care and the potential of our proprietary cannabinoid formulation.

GBM highly expresses the CB2 cannabinoid receptor, and our hypothesis is that CBD ‘opens up’ cell pathways and makes them more susceptible to chemotherapy. As prior studies have shown much promise, we are optimistic this Phase I/II clinical trial will encourage further research with the goal of adding a new treatment for those living with glioblastoma.

This Is Big News

For some time now, it has been believed that CBD has various applications in the healthcare setting, especially in oncology. With this announcement AMERI Holdings becomes one of only a select few cannabis companies that is not just saying that cannabis helps with healthcare, but working to prove it.

If the study is approved in the summer, it will act as a huge catalyst. In fact, today’s news sets a domino effect into place for several catalysts to come. Approval of the study, initiation, first patient treated, preliminary results, and results all have the potential to lead to tremendous gains ahead.

So, if you’re not watching AMRH yet, now is the time to start!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.